LCN2 and psoriasis: Consistent with our findings, the neutralization of LCN2 has been shown to control neutrophilic inflammation in experimental disease models of psoriasis, cardiovascular disease, alcoholic steatohepatitis, and nonalcoholic steatohepatitis [49].